Genmab to File sBLA with FDA for Epcoritamab in Combination with R2 Regimen for Relapsed/Refractory Follicular Lymphoma

Genmab to Submit sBLA to FDA for Epcoritamab in Combination with Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma Genmab A/S (Nasdaq: GMAB) has announced its plan to submit a supplemental Biologics License Application (sBLA) to the U.S. Food…

Read MoreGenmab to File sBLA with FDA for Epcoritamab in Combination with R2 Regimen for Relapsed/Refractory Follicular Lymphoma

InnoCare Advances as Zurletrectinib Gets Priority Review by China’s NMPA

InnoCare’s Next-Generation TRK Inhibitor Zurletrectinib Granted Priority Review by China’s NMPA for NTRK Fusion-Positive Tumors A prominent biopharmaceutical company dedicated to the development of innovative therapies for cancer and autoimmune diseases, announced a major regulatory milestone today. The Center for…

Read MoreInnoCare Advances as Zurletrectinib Gets Priority Review by China’s NMPA

Chelsea Jordan Named VP of Data Integration & Payroll at Creative Solutions in Healthcare

Creative Solutions in Healthcare Promotes Chelsea Jordan to Vice President of Data Integration and Payroll, Reinforcing Commitment to Innovation and Operational Excellence Creative Solutions in Healthcare, the nation’s largest privately held skilled nursing provider, has announced the promotion of Chelsea…

Read MoreChelsea Jordan Named VP of Data Integration & Payroll at Creative Solutions in Healthcare